APOE4 does not simply increase inflammation. It may alter how inflammatory responses are resolved, creating tissue-specific vulnerability. The risk is context-dependent.
Noncontrast CT (Caristo, FDA approved) is a cheaper technology. It could screen Apo E4 carriers for NONSPECIFIC brain inflammation in targeted areas. You Ca+PLA2 AA Pet could then be used in a more specific fashion. At least that's my thinking.
What’s wild is we now seem to know that apoe4 carriers have genetically higher cPLA2 activities yet are not really pushing lithium yet as a method to slow it down over a lifetime. We are waiting for a more perfect drug…but I’m not sure what’s wrong with lithium? Not medical advice just speculating based on what I’ve read!
Of course, Zeus is not a done deal. I've only read the press release. But perhaps picking CKD patients with CV disease is just the wrong patient population. They may be just too sick to benefit. Or maybe the true target is IL-1.
Well reasoned, well written. It reminds me of Eric Topol's recent comments concerning IL-6 inhibition and pinpointing where the inflammation is taking place. For the coronary arteries, FAI (fat attenuation index) applied to a non contrast CT could be used. If the coronary periarterial fat were inflamed, IL-6 blockade might work better. Could FAI be developed for the brain?
APOE4 does not simply increase inflammation. It may alter how inflammatory responses are resolved, creating tissue-specific vulnerability. The risk is context-dependent.
*** sex dependent!
Noncontrast CT (Caristo, FDA approved) is a cheaper technology. It could screen Apo E4 carriers for NONSPECIFIC brain inflammation in targeted areas. You Ca+PLA2 AA Pet could then be used in a more specific fashion. At least that's my thinking.
What’s wild is we now seem to know that apoe4 carriers have genetically higher cPLA2 activities yet are not really pushing lithium yet as a method to slow it down over a lifetime. We are waiting for a more perfect drug…but I’m not sure what’s wrong with lithium? Not medical advice just speculating based on what I’ve read!
Of course, Zeus is not a done deal. I've only read the press release. But perhaps picking CKD patients with CV disease is just the wrong patient population. They may be just too sick to benefit. Or maybe the true target is IL-1.
I doubt this but timewill tell.
I’m looking at IL-17f inhibition with great interest as a female apoe4 carrier!
Well reasoned, well written. It reminds me of Eric Topol's recent comments concerning IL-6 inhibition and pinpointing where the inflammation is taking place. For the coronary arteries, FAI (fat attenuation index) applied to a non contrast CT could be used. If the coronary periarterial fat were inflamed, IL-6 blockade might work better. Could FAI be developed for the brain?
Thanks!
We are developing PET imaging to see PUFA metabolism in the brain
And we can’t wait! 🥳❤️
Layman here…EPA is good, DHA is not good?
Not really
Both are good but not as supplements
Its how the body makes and breaks them what matters
And a good whole diet with exercise helps the metabolism of these omega3s